Since the introduction of interferon-α (IFN) as a treatment for CML [1], [2], randomized trials have shown that it is able to induce hematological remission in 70–80% cases and cytogenetic remission in 35–55% cases [3]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.